Patent · US Active

Fully human antibody against human CD 137

US10875926B2 · kind B2 · utility

1Cited by

0References

13Claims

0Family size

Assignee

DINGFU BIOTARGET CO., LTD. · CN

Inventors

Ting Xu · Berkeley, US
Yan Luan · 安丰镇, CN
Xiaoxiao Wang · Tangxia, CN
Jianjian PENG · 安丰镇, CN
Shuli Ma · 安丰镇, CN
Hui Ma · Tuji, CN
Xiaolong PAN · 安丰镇, CN
Shilong FU · 安丰镇, CN
Shanshan NING · 安丰镇, CN
Yeqiong Fei · 安丰镇, CN
Meng ZHAO · 安丰镇, CN

Key dates

Filing date	Sep 22, 2015
Grant date	Dec 29, 2020
Priority date	—
Expiry date	Apr 12, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof. a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.